Results 11 to 20 of about 126,141 (353)

JAK inhibitors and alopecia areata [PDF]

The Lancet, 2019
Amos, Gilhar, Aviad, Keren, Ralf, Paus
openaire   +4 more sources

JAK Inhibitors in Rheumatoid Arthritis

European Medical Journal Allergy & Immunology, 2022
JAK inhibitors (JAKi) are targeted, small-molecule, disease-modifying therapies that are the newest class of treatments to emerge for the management of rheumatoid arthritis (RA) and the first oral disease-modifying anti-rheumatic drugs (DMARD) to ...
Kathryn Biddle, Jonathan PE White, Nidhi Sofat   +2 more
doaj   +1 more source

JAK inhibitors for asthma

Journal of Allergy and Clinical Immunology, 2021
Asthma is an inflammatory disease of the airways characterized by intermittent episodes of wheezing, chest tightness, and cough. Many of the inflammatory pathways implicated in asthma involve cytokines and growth factors that activate Janus kinases (JAKs).
Steve N, Georas, Patrick, Donohue, Margaret, Connolly, Michael E, Wechsler   +3 more
openaire   +3 more sources

Janus kinase inhibitors in autoimmune bullous diseases

Frontiers in Immunology, 2023
Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang, Dawei Huang, Yuexin Zhang, Yuexin Zhang, Luyang Kong, Luyang Kong, Jiajing Lu, Jiajing Lu, Yuling Shi, Yuling Shi   +9 more
doaj   +1 more source

JAK inhibitors: Ten years after

European Journal of Immunology, 2021
AbstractThe European Journal of Immunology was launched 50 years ago, coinciding with the discovery of many cytokines and growth factors and the emergence of an entirely new field of research. Ultimately, our knowledge about the biological activity of these factors allowed us to better understand how the immune system functions in the context of ...
Francesca Romana Spinelli, Françoise Meylan, John J. O'Shea, Massimo Gadina   +3 more
openaire   +4 more sources

JAK inhibitors in autoinflammation [PDF]

Journal of Clinical Investigation, 2018
Interferonopathies are a subset of autoinflammatory disorders with a prominent type I IFN gene signature. Treatment of these patients has been challenging, given the lack of response to common autoinflammatory therapeutics including IL-1 and TNF blockade.
Hal M, Hoffman, Lori, Broderick
openaire   +2 more sources

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review. [PDF]

Int J Mol Sci
Böll SL, Seyed Jafari SM, Conrad C, Schlapbach C.   +3 more
europepmc   +2 more sources

Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence

JID Innovations, 2023
Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab, tralokinumab, and nemolizumab. The increase in treatment options can be a
Masahiro Kamata, Yayoi Tada
doaj   +1 more source

Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune‐Mediated Inflammatory Diseases: A Systematic Review and Meta‐Analysis of Randomized Trials

ACR Open Rheumatology, 2022
Objective Janus kinase (JAK) inhibition effectively treats immune‐mediated inflammatory diseases (IMIDs); however, concern over the risk of major adverse cardiac events (MACE) and venous thromboembolism (VTE) remains. We aimed to evaluate the safety (VTE
Muhammad Haisum Maqsood, Brittany N. Weber, Rebecca H. Haberman, Kristen I. Lo Sicco, Sripal Bangalore, Michael S. Garshick   +5 more
doaj   +1 more source

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P., Lagana, B., Pioli, C., Rosado, M. M., Sesti, G.   +4 more
core   +2 more sources